<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01077596</url>
  </required_header>
  <id_info>
    <org_study_id>111982</org_study_id>
    <secondary_id>EPI40463</secondary_id>
    <secondary_id>WEUKSTV1113</secondary_id>
    <nct_id>NCT01077596</nct_id>
  </id_info>
  <brief_title>Carcinogenicity Study of Bupropion</brief_title>
  <official_title>Post-marketing Carcinogenicity Study of Bupropion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is a lack of toxicology data on one bupropion metabolite, and limited literature
      examining bupropion use and cancer risk. This study evaluates the association between
      bupropion exposure and the development of cancer of the prostate, breast, lung, colon/rectum,
      urinary bladder, and uterus by comparing the risk of cancer in bupropion users with other
      antidepressant users. Because there is no evidence that bupropion is associated with any
      particular cancer, we have chosen the six most common cancers diagnosed in the United States
      to optimize statistical power/precision for cancer-site specific comparisons. Two US
      population-based data resources with automated claims, pharmacy, and tumor registry data are
      included in this study. Using a nested case-control design, this study will compare the
      incidence of cancer in patients exposed to bupropion with the incidence in patients exposed
      to other antidepressants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients were not recruited for nor enrolled in this study. This study is a retrospective
      observational study. Data from medical records or insurance claims databases are anonymised
      and used to develop a patient cohort. All diagnoses and treatment are recorded in the course
      of routine medical practice.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Diagnosed With Any of the Cancers Under Investigation Who Were Regularly Exposed to the Indicated Antidepressant</measure>
    <time_frame>January 1, 1996 - December 31, 2006</time_frame>
    <description>The following are the cancers under investigation: colorectal, lung, bladder, uterus, breast, and prostate. Cancer case were nested within a cohort of new antidepressant users. New antidepressant users were defined as no previous antidepressant prescription in the previous 6 months. Cases were identified and matched with controls from the same new-user cohort. Cal year, calendar year; dx, diagnosis; IBD, Inflammatory Bowel Disease; OC, oral contraceptive; HRT/ERT, hormone replacement therapy/estrogen replacement therapy; NSAID, non-steroidal anti-inflammatory drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Diagnosed With Colorectal Cancer Who Were Regularly Exposed to the Indicated Antidepressant</measure>
    <time_frame>January 1, 1996 - December 31, 2006</time_frame>
    <description>In this outcome, colorectal cancer is under investigation: Cancer case were nested within a cohort of new antidepressant users. New antidepressant users were defined as no previous antidepressant prescription in the previous 6 months. Colorectal cancer cases were identified and matched with controls from the same new-user cohort. Cal year, calendar year; dx, diagnosis; IBD, Inflammatory Bowel Disease; OC, oral contraceptive; HRT/ERT, hormone replacement therapy/estrogen replacement therapy; NSAID, non-steroidal anti-inflammatory drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Diagnosed With Lung Cancer Who Were Regularly Exposed to the Indicated Antidepressant</measure>
    <time_frame>January 1, 1996 - December 31, 2006</time_frame>
    <description>In this outcome, lung cancer is under investigation: Cancer case were nested within a cohort of new antidepressant users. New antidepressant users were defined as no previous antidepressant prescription in the previous 6 months. Lung cancer cases were identified and matched with controls from the same new-user cohort. Cal year, calendar year; dx, diagnosis; IBD, Inflammatory Bowel Disease; OC, oral contraceptive; HRT/ERT, hormone replacement therapy/estrogen replacement therapy; NSAID, non-steroidal anti-inflammatory drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Diagnosed With Bladder Cancer Who Were Regularly Exposed to the Indicated Antidepressant</measure>
    <time_frame>January 1, 1996 - December 31, 2006</time_frame>
    <description>In this outcome, bladder cancer is under investigation: Cancer case were nested within a cohort of new antidepressant users. New antidepressant users were defined as no previous antidepressant prescription in the previous 6 months. Bladder cancer cases were identified and matched with controls from the same new-user cohort. Cal year, calendar year; dx, diagnosis; IBD, Inflammatory Bowel Disease; OC, oral contraceptive; HRT/ERT, hormone replacement therapy/estrogen replacement therapy; NSAID, non-steroidal anti-inflammatory drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Diagnosed With Uterine Cancer Who Were Regularly Exposed to the Indicated Antidepressant</measure>
    <time_frame>January 1, 1996 - December 31, 2006</time_frame>
    <description>In this outcome, uterine cancer is under investigation: Cancer case were nested within a cohort of new antidepressant users. New antidepressant users were defined as no previous antidepressant prescription in the previous 6 months. Uterine cancer cases were identified and matched with controls from the same new-user cohort. Cal year, calendar year; dx, diagnosis; IBD, Inflammatory Bowel Disease; OC, oral contraceptive; HRT/ERT, hormone replacement therapy/estrogen replacement therapy; NSAID, non-steroidal anti-inflammatory drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Diagnosed With Breast Cancer Who Were Regularly Exposed to the Indicated Antidepressant</measure>
    <time_frame>January 1, 1996 - December 31, 2006</time_frame>
    <description>In this outcome, breast cancer is under investigation: Cancer case were nested within a cohort of new antidepressant users. New antidepressant users were defined as no previous antidepressant prescription in the previous 6 months. Breast cancer cases were identified and matched with controls from the same new-user cohort. Cal year, calendar year; dx, diagnosis; IBD, Inflammatory Bowel Disease; OC, oral contraceptive; HRT/ERT, hormone replacement therapy/estrogen replacement therapy; NSAID, non-steroidal anti-inflammatory drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Diagnosed With Prostate Cancer Who Were Regularly Exposed to the Indicated Antidepressant</measure>
    <time_frame>January 1, 1996 - December 31, 2006</time_frame>
    <description>In this outcome, prostate cancer is under investigation: Cancer case were nested within a cohort of new antidepressant users. New antidepressant users were defined as no previous antidepressant prescription in the previous 6 months. Prostate cancer cases were identified and matched with controls from the same new-user cohort. Cal year, calendar year; dx, diagnosis; IBD, Inflammatory Bowel Disease; OC, oral contraceptive; HRT/ERT, hormone replacement therapy/estrogen replacement therapy; NSAID, non-steroidal anti-inflammatory drug.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">50430</enrollment>
  <condition>Depressive Disorder</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>New users of antidepressants Jan. 1, 1996 to Dec. 31, 2006</arm_group_label>
    <description>All new users of antidepressants January 1, 1996 through December 31, 2006. Individuals 18 years of age or older with medical and pharmacy benefits and at least 6 months of health plan enrollment before the first antidepressant prescription.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regular bupropion use</intervention_name>
    <description>Regular use of bupropion is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date.</description>
    <arm_group_label>New users of antidepressants Jan. 1, 1996 to Dec. 31, 2006</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regular SSRI (Selective serotonin reuptake inhibitors) use</intervention_name>
    <description>Regular use of SSRI is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date.</description>
    <arm_group_label>New users of antidepressants Jan. 1, 1996 to Dec. 31, 2006</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regular TCA (Tricyclic antidepressants) use</intervention_name>
    <description>Regular use of TCA is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date.</description>
    <arm_group_label>New users of antidepressants Jan. 1, 1996 to Dec. 31, 2006</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regular use of any other antidepressant</intervention_name>
    <description>Regular use of any other antidepressants is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date. An &quot;other antidepressant&quot; would be any antidepressant other than bupropion, a SSRI or a TCA.</description>
    <arm_group_label>New users of antidepressants Jan. 1, 1996 to Dec. 31, 2006</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        New users of antidepressants January 1, 1996 through December 31, 2006, regardless of
        indication for use (depression, smoking cessation, other) in Henry Ford Health System and
        Kaiser Permanente Health Plan of Northern California. The study population is limited to
        individuals 18 years of age or older with medical and pharmacy benefits and at least 6
        months of health plan enrollment before the first antidepressant prescription. Patients
        with a history of any cancer (cancer diagnosis recorded in the tumor registries anytime
        before the first antidepressant prescription recorded during the study period) are
        excluded. Cases and controls will be selected from this cohort of antidepressant-exposed
        study subjects.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Exclusion Criteria:

          -  Cancers diagnosed within 12 months of initiation (i.e., new use) of antidepressant
             pharmacotherapy will be excluded to account for a minimum period for the development
             of cancer (cancer latency) and to be consistent with other studies of antidepressants
             and cancer.

          -  Patients with a history of any cancer (cancer diagnosis recorded in the tumor
             registries anytime before the first antidepressant prescription recorded during the
             study period)

          -  Any antidepressant use within 6 months of January 1, 1996
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2010</study_first_submitted>
  <study_first_submitted_qc>February 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2010</study_first_posted>
  <results_first_submitted>January 21, 2011</results_first_submitted>
  <results_first_submitted_qc>January 21, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 10, 2011</results_first_posted>
  <last_update_submitted>May 25, 2017</last_update_submitted>
  <last_update_submitted_qc>May 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Carcinogenicity</keyword>
  <keyword>Case control</keyword>
  <keyword>Bupropion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
    <mesh_term>Bupropion</mesh_term>
    <mesh_term>Serotonin</mesh_term>
    <mesh_term>Serotonin Uptake Inhibitors</mesh_term>
    <mesh_term>Antidepressive Agents, Tricyclic</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were not recruited for nor enrolled in this study. This study is a retrospective observational study. Data from medical records or insurance claims databases are anonymized and used to develop a patient cohort. All diagnoses and treatment are recorded in the course of routine medical practice.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>New Antidepressant Exposure in Colorectal Cancer: Cases</title>
          <description>New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Colorectal Cancer: Cases</description>
        </group>
        <group group_id="P2">
          <title>New Antidepressant Exposure in Colorectal Cancer: Controls</title>
          <description>New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Colorectal Cancer: Controls</description>
        </group>
        <group group_id="P3">
          <title>New Antidepressant Exposure in Lung Cancer: Cases</title>
          <description>New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Lung Cancer: Cases</description>
        </group>
        <group group_id="P4">
          <title>New Antidepressant Exposure in Lung Cancer: Controls</title>
          <description>New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Lung Cancer: Controls</description>
        </group>
        <group group_id="P5">
          <title>New Antidepressant Exposure in Bladder Cancer: Cases</title>
          <description>New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Bladder Cancer: Cases</description>
        </group>
        <group group_id="P6">
          <title>New Antidepressant Exposure in Bladder Cancer: Controls</title>
          <description>New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Bladder Cancer: Controls</description>
        </group>
        <group group_id="P7">
          <title>Antidepressant Exposure in Uterine Cancer: Cases</title>
          <description>New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Uterine Cancer: Cases</description>
        </group>
        <group group_id="P8">
          <title>New Antidepressant Exposure in Uterine Cancer: Controls</title>
          <description>New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Uterine Cancer: Controls</description>
        </group>
        <group group_id="P9">
          <title>New Antidepressant Exposure in Breast Cancer: Cases</title>
          <description>New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Breast Cancer: Cases</description>
        </group>
        <group group_id="P10">
          <title>New Antidepressant Exposure in Breast Cancer: Controls</title>
          <description>New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Breast Cancer: Controls</description>
        </group>
        <group group_id="P11">
          <title>New Antidepressant Exposure in Prostate Cancer: Cases</title>
          <description>New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Prostate Cancer: Cases</description>
        </group>
        <group group_id="P12">
          <title>New Antidepressant Exposure in Prostate Cancer: Controls</title>
          <description>New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Prostate Cancer: Controls</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="350"/>
                <participants group_id="P2" count="1050"/>
                <participants group_id="P3" count="457"/>
                <participants group_id="P4" count="1370"/>
                <participants group_id="P5" count="294"/>
                <participants group_id="P6" count="882"/>
                <participants group_id="P7" count="308"/>
                <participants group_id="P8" count="837"/>
                <participants group_id="P9" count="2842"/>
                <participants group_id="P10" count="28420"/>
                <participants group_id="P11" count="2215"/>
                <participants group_id="P12" count="22150"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="350"/>
                <participants group_id="P2" count="1050"/>
                <participants group_id="P3" count="457"/>
                <participants group_id="P4" count="1370"/>
                <participants group_id="P5" count="294"/>
                <participants group_id="P6" count="882"/>
                <participants group_id="P7" count="308"/>
                <participants group_id="P8" count="837"/>
                <participants group_id="P9" count="2842"/>
                <participants group_id="P10" count="28420"/>
                <participants group_id="P11" count="2215"/>
                <participants group_id="P12" count="22150"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>New Antidepressant Exposure in Colorectal Cancer: Cases</title>
          <description>New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Colorectal Cancer: Cases</description>
        </group>
        <group group_id="B2">
          <title>New Antidepressant Exposure in Colorectal Cancer: Controls</title>
          <description>New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Colorectal Cancer: Controls</description>
        </group>
        <group group_id="B3">
          <title>New Antidepressant Exposure in Lung Cancer: Cases</title>
          <description>New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Lung Cancer: Cases</description>
        </group>
        <group group_id="B4">
          <title>New Antidepressant Exposure in Lung Cancer: Controls</title>
          <description>New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Lung Cancer: Controls</description>
        </group>
        <group group_id="B5">
          <title>New Antidepressant Exposure in Bladder Cancer: Cases</title>
          <description>New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Bladder Cancer: Cases</description>
        </group>
        <group group_id="B6">
          <title>New Antidepressant Exposure in Bladder Cancer: Controls</title>
          <description>New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Bladder Cancer: Controls</description>
        </group>
        <group group_id="B7">
          <title>New Antidepressant Exposure in Uterine Cancer: Cases</title>
          <description>New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Uterine Cancer: Cases</description>
        </group>
        <group group_id="B8">
          <title>New Antidepressant Exposure in Uterine Cancer: Controls</title>
          <description>New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Uterine Cancer: Controls</description>
        </group>
        <group group_id="B9">
          <title>New Antidepressant Exposure in Breast Cancer: Cases</title>
          <description>New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Breast Cancer: Cases</description>
        </group>
        <group group_id="B10">
          <title>New Antidepressant Exposure in Breast Cancer: Controls</title>
          <description>New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Breast Cancer: Controls</description>
        </group>
        <group group_id="B11">
          <title>New Antidepressant Exposure in Prostate Cancer: Cases</title>
          <description>New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Prostate Cancer: Cases</description>
        </group>
        <group group_id="B12">
          <title>New Antidepressant Exposure in Prostate Cancer: Controls</title>
          <description>New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Prostate Cancer: Controls</description>
        </group>
        <group group_id="B13">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="350"/>
            <count group_id="B2" value="1050"/>
            <count group_id="B3" value="457"/>
            <count group_id="B4" value="1370"/>
            <count group_id="B5" value="294"/>
            <count group_id="B6" value="882"/>
            <count group_id="B7" value="308"/>
            <count group_id="B8" value="837"/>
            <count group_id="B9" value="2842"/>
            <count group_id="B10" value="28420"/>
            <count group_id="B11" value="2215"/>
            <count group_id="B12" value="22150"/>
            <count group_id="B13" value="61175"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>45-54 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="140"/>
                    <measurement group_id="B5" value="17"/>
                    <measurement group_id="B6" value="51"/>
                    <measurement group_id="B7" value="59"/>
                    <measurement group_id="B8" value="172"/>
                    <measurement group_id="B9" value="678"/>
                    <measurement group_id="B10" value="6780"/>
                    <measurement group_id="B11" value="193"/>
                    <measurement group_id="B12" value="1930"/>
                    <measurement group_id="B13" value="10203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>55-64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="219"/>
                    <measurement group_id="B3" value="102"/>
                    <measurement group_id="B4" value="306"/>
                    <measurement group_id="B5" value="63"/>
                    <measurement group_id="B6" value="189"/>
                    <measurement group_id="B7" value="90"/>
                    <measurement group_id="B8" value="245"/>
                    <measurement group_id="B9" value="849"/>
                    <measurement group_id="B10" value="8490"/>
                    <measurement group_id="B11" value="669"/>
                    <measurement group_id="B12" value="6690"/>
                    <measurement group_id="B13" value="17985"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>65-74 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="357"/>
                    <measurement group_id="B3" value="159"/>
                    <measurement group_id="B4" value="477"/>
                    <measurement group_id="B5" value="104"/>
                    <measurement group_id="B6" value="312"/>
                    <measurement group_id="B7" value="84"/>
                    <measurement group_id="B8" value="224"/>
                    <measurement group_id="B9" value="707"/>
                    <measurement group_id="B10" value="7070"/>
                    <measurement group_id="B11" value="877"/>
                    <measurement group_id="B12" value="8770"/>
                    <measurement group_id="B13" value="19260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                    <measurement group_id="B2" value="372"/>
                    <measurement group_id="B3" value="149"/>
                    <measurement group_id="B4" value="447"/>
                    <measurement group_id="B5" value="110"/>
                    <measurement group_id="B6" value="330"/>
                    <measurement group_id="B7" value="75"/>
                    <measurement group_id="B8" value="196"/>
                    <measurement group_id="B9" value="608"/>
                    <measurement group_id="B10" value="6080"/>
                    <measurement group_id="B11" value="476"/>
                    <measurement group_id="B12" value="4760"/>
                    <measurement group_id="B13" value="13727"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                    <measurement group_id="B2" value="378"/>
                    <measurement group_id="B3" value="175"/>
                    <measurement group_id="B4" value="525"/>
                    <measurement group_id="B5" value="91"/>
                    <measurement group_id="B6" value="273"/>
                    <measurement group_id="B7" value="308"/>
                    <measurement group_id="B8" value="837"/>
                    <measurement group_id="B9" value="2842"/>
                    <measurement group_id="B10" value="28420"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="33975"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="224"/>
                    <measurement group_id="B2" value="672"/>
                    <measurement group_id="B3" value="282"/>
                    <measurement group_id="B4" value="845"/>
                    <measurement group_id="B5" value="203"/>
                    <measurement group_id="B6" value="609"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="2215"/>
                    <measurement group_id="B12" value="22150"/>
                    <measurement group_id="B13" value="27200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants diagnosed with the indicated conditions and using the indicated therapies</title>
          <description>A value of “0” indicates that no data are available for that particular treatment arm. Smoking status data were not collected for breast cancer and prostate cancer cases and controls, as it is not a necessary variable for analysis. NSAIDS, non-steroidal anti-inflammatory drugs.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Exposed to multiple antidepressants</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="160"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="191"/>
                    <measurement group_id="B5" value="44"/>
                    <measurement group_id="B6" value="147"/>
                    <measurement group_id="B7" value="53"/>
                    <measurement group_id="B8" value="162"/>
                    <measurement group_id="B9" value="564"/>
                    <measurement group_id="B10" value="5756"/>
                    <measurement group_id="B11" value="340"/>
                    <measurement group_id="B12" value="3782"/>
                    <measurement group_id="B13" value="11308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ever smokers</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="252"/>
                    <measurement group_id="B2" value="643"/>
                    <measurement group_id="B3" value="428"/>
                    <measurement group_id="B4" value="772"/>
                    <measurement group_id="B5" value="247"/>
                    <measurement group_id="B6" value="573"/>
                    <measurement group_id="B7" value="142"/>
                    <measurement group_id="B8" value="389"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="3446"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown smoking status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="183"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="29"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="27"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ever diagnosed (dx) with depression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="329"/>
                    <measurement group_id="B3" value="108"/>
                    <measurement group_id="B4" value="408"/>
                    <measurement group_id="B5" value="83"/>
                    <measurement group_id="B6" value="273"/>
                    <measurement group_id="B7" value="119"/>
                    <measurement group_id="B8" value="319"/>
                    <measurement group_id="B9" value="1091"/>
                    <measurement group_id="B10" value="10541"/>
                    <measurement group_id="B11" value="677"/>
                    <measurement group_id="B12" value="6700"/>
                    <measurement group_id="B13" value="20758"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ever dx with inflammatory bowel disease (IBD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Users of oral contraceptives (OC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="45"/>
                    <measurement group_id="B9" value="236"/>
                    <measurement group_id="B10" value="1987"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="2289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Users of hormone replacement therapy (HRT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="225"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="153"/>
                    <measurement group_id="B8" value="441"/>
                    <measurement group_id="B9" value="1796"/>
                    <measurement group_id="B10" value="17184"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="19856"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Users of NSAIDs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="269"/>
                    <measurement group_id="B2" value="859"/>
                    <measurement group_id="B3" value="370"/>
                    <measurement group_id="B4" value="1123"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="2340"/>
                    <measurement group_id="B10" value="23730"/>
                    <measurement group_id="B11" value="1800"/>
                    <measurement group_id="B12" value="17887"/>
                    <measurement group_id="B13" value="48378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Diagnosed With Any of the Cancers Under Investigation Who Were Regularly Exposed to the Indicated Antidepressant</title>
        <description>The following are the cancers under investigation: colorectal, lung, bladder, uterus, breast, and prostate. Cancer case were nested within a cohort of new antidepressant users. New antidepressant users were defined as no previous antidepressant prescription in the previous 6 months. Cases were identified and matched with controls from the same new-user cohort. Cal year, calendar year; dx, diagnosis; IBD, Inflammatory Bowel Disease; OC, oral contraceptive; HRT/ERT, hormone replacement therapy/estrogen replacement therapy; NSAID, non-steroidal anti-inflammatory drug.</description>
        <time_frame>January 1, 1996 – December 31, 2006</time_frame>
        <population>Participants diagnosed with colorectal, lung, bladder, uterus, breast, or prostate cancer who were new antidepressant users</population>
        <group_list>
          <group group_id="O1">
            <title>Bupropion, Regular Use</title>
            <description>Regular Bupropion use was defined as 4 times per week for 3 months at least 12 months before index date</description>
          </group>
          <group group_id="O2">
            <title>All Non-bupropion Antidepressants, Regular Use</title>
            <description>Regular antidepressant use of non-bupropion was defined as use of non-bupropion antidepressant for 4 times per week for 3 months at least 12 months before index date</description>
          </group>
          <group group_id="O3">
            <title>Tricyclic Antidepressants (TCA), Regular Use</title>
            <description>Regular TCA use was defined as use of TCA for 4 times per week for 3 months at least 12 months before index date</description>
          </group>
          <group group_id="O4">
            <title>Selective Serotonin Reuptake Inhibitors (SSRI), Regular Use</title>
            <description>Regular SSRI use was defined as use of SSRI antidepressant for 4 times per week for 3 months at least 12 months before index date</description>
          </group>
          <group group_id="O5">
            <title>Other Antidepressants, Regular Use</title>
            <description>Regular “other” antidepressant use was defined as use other antidepressant aside from Bupropion, TCA, and SSRI for 4 times per week for 3 months at least 12 months before index date</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Diagnosed With Any of the Cancers Under Investigation Who Were Regularly Exposed to the Indicated Antidepressant</title>
          <description>The following are the cancers under investigation: colorectal, lung, bladder, uterus, breast, and prostate. Cancer case were nested within a cohort of new antidepressant users. New antidepressant users were defined as no previous antidepressant prescription in the previous 6 months. Cases were identified and matched with controls from the same new-user cohort. Cal year, calendar year; dx, diagnosis; IBD, Inflammatory Bowel Disease; OC, oral contraceptive; HRT/ERT, hormone replacement therapy/estrogen replacement therapy; NSAID, non-steroidal anti-inflammatory drug.</description>
          <population>Participants diagnosed with colorectal, lung, bladder, uterus, breast, or prostate cancer who were new antidepressant users</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8038"/>
                <count group_id="O2" value="42392"/>
                <count group_id="O3" value="18537"/>
                <count group_id="O4" value="23740"/>
                <count group_id="O5" value="10123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cases</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="853"/>
                    <measurement group_id="O2" value="4561"/>
                    <measurement group_id="O3" value="1963"/>
                    <measurement group_id="O4" value="2570"/>
                    <measurement group_id="O5" value="1027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Controls</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6332"/>
                    <measurement group_id="O2" value="37831"/>
                    <measurement group_id="O3" value="16574"/>
                    <measurement group_id="O4" value="21170"/>
                    <measurement group_id="O5" value="9096"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Crude Odds Ratio</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.1</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.0</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
            <estimate_desc>Adjusted for age, sex, cal year, study site, tumor characteristics, multiple antidepressants exposure, smoking, hysterectomy status, previous depression dx, previous IBD diagnosis, OC use, HRT/ERT use, and NSAID use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Crude Odds Ratio</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.1</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.0</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
            <estimate_desc>Adjusted for age, sex, cal year, study site, tumor characteristics, multiple antidepressants exposure, smoking, hysterectomy status, previous depression dx, previous IBD diagnosis, OC use, HRT/ERT use, and NSAID use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Crude Odds Ratio</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.0</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.0</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
            <estimate_desc>Adjusted for age, sex, cal year, study site, tumor characteristics, multiple antidepressants exposure, smoking, hysterectomy status, previous depression dx, previous IBD diagnosis, OC use, HRT/ERT use, and NSAID use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Crude Odds Ratio</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.1</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.0</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
            <estimate_desc>Adjusted for age, sex, cal year, study site, tumor characteristics, multiple antidepressants exposure, smoking, hysterectomy status, previous depression dx, previous IBD diagnosis, OC use, HRT/ERT use, and NSAID use.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Diagnosed With Colorectal Cancer Who Were Regularly Exposed to the Indicated Antidepressant</title>
        <description>In this outcome, colorectal cancer is under investigation: Cancer case were nested within a cohort of new antidepressant users. New antidepressant users were defined as no previous antidepressant prescription in the previous 6 months. Colorectal cancer cases were identified and matched with controls from the same new-user cohort. Cal year, calendar year; dx, diagnosis; IBD, Inflammatory Bowel Disease; OC, oral contraceptive; HRT/ERT, hormone replacement therapy/estrogen replacement therapy; NSAID, non-steroidal anti-inflammatory drug.</description>
        <time_frame>January 1, 1996 – December 31, 2006</time_frame>
        <population>Participants diagnosed with colorectal cancer who were new antidepressant users.</population>
        <group_list>
          <group group_id="O1">
            <title>Bupropion, Regular Use</title>
            <description>Regular Bupropion use was defined as 4 times per week for 3 months at least 12 months before index date</description>
          </group>
          <group group_id="O2">
            <title>All Non-bupropion Antidepressants, Regular Use</title>
            <description>Regular antidepressant use of non-bupropion was defined as use of non-bupropion antidepressant for 4 times per week for 3 months at least 12 months before index date</description>
          </group>
          <group group_id="O3">
            <title>Tricyclic Antidepressants (TCA), Regular Use</title>
            <description>Regular TCA use was defined as use of tricyclic antidepressant for 4 times per week for 3 months at least 12 months before index date</description>
          </group>
          <group group_id="O4">
            <title>Selective Serotonin Reuptake Inhibitors (SSRI), Regular Use</title>
            <description>Regular SSRI use was defined as use of SSRI antidepressant for 4 times per week for 3 months at least 12 months before index date</description>
          </group>
          <group group_id="O5">
            <title>Other Antidepressants, Regular Use</title>
            <description>Regular ‘other’ antidepressant use was defined as use other antidepressant aside from Bupropion, TCA and SSRI for 4 times per week for 3 months at least 12 months before index date</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Diagnosed With Colorectal Cancer Who Were Regularly Exposed to the Indicated Antidepressant</title>
          <description>In this outcome, colorectal cancer is under investigation: Cancer case were nested within a cohort of new antidepressant users. New antidepressant users were defined as no previous antidepressant prescription in the previous 6 months. Colorectal cancer cases were identified and matched with controls from the same new-user cohort. Cal year, calendar year; dx, diagnosis; IBD, Inflammatory Bowel Disease; OC, oral contraceptive; HRT/ERT, hormone replacement therapy/estrogen replacement therapy; NSAID, non-steroidal anti-inflammatory drug.</description>
          <population>Participants diagnosed with colorectal cancer who were new antidepressant users.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="973"/>
                <count group_id="O3" value="432"/>
                <count group_id="O4" value="545"/>
                <count group_id="O5" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cases</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="234"/>
                    <measurement group_id="O3" value="111"/>
                    <measurement group_id="O4" value="134"/>
                    <measurement group_id="O5" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Controls</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="739"/>
                    <measurement group_id="O3" value="321"/>
                    <measurement group_id="O4" value="411"/>
                    <measurement group_id="O5" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Crude Odds Ratio</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>2.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.8</ci_lower_limit>
            <ci_upper_limit>2.0</ci_upper_limit>
            <estimate_desc>Adjusted for age, sex, cal year, study site, tumor characteristics, multiple antidepressants exposure, smoking, hysterectomy status, previous depression dx, previous IBD diagnosis, OC use, HRT/ERT use, and NSAID use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Crude Odds Ratio</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.8</ci_lower_limit>
            <ci_upper_limit>2.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.7</ci_lower_limit>
            <ci_upper_limit>1.9</ci_upper_limit>
            <estimate_desc>Adjusted for age, sex, cal year, study site, tumor characteristics, multiple antidepressants exposure, smoking, hysterectomy status, previous depression dx, previous IBD diagnosis, OC use, HRT/ERT use, and NSAID use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Crude Odds Ratio</param_type>
            <param_value>1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.8</ci_lower_limit>
            <ci_upper_limit>2.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.7</ci_lower_limit>
            <ci_upper_limit>1.9</ci_upper_limit>
            <estimate_desc>Adjusted for age, sex, cal year, study site, tumor characteristics, multiple antidepressants exposure, smoking, hysterectomy status, previous depression dx, previous IBD diagnosis, OC use, HRT/ERT use, and NSAID use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Crude Odds Ratio</param_type>
            <param_value>2.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.2</ci_lower_limit>
            <ci_upper_limit>3.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>2.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.1</ci_lower_limit>
            <ci_upper_limit>3.6</ci_upper_limit>
            <estimate_desc>Adjusted for age, sex, cal year, study site, tumor characteristics, multiple antidepressants exposure, smoking, hysterectomy status, previous depression dx, previous IBD diagnosis, OC use, HRT/ERT use, and NSAID use.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Diagnosed With Lung Cancer Who Were Regularly Exposed to the Indicated Antidepressant</title>
        <description>In this outcome, lung cancer is under investigation: Cancer case were nested within a cohort of new antidepressant users. New antidepressant users were defined as no previous antidepressant prescription in the previous 6 months. Lung cancer cases were identified and matched with controls from the same new-user cohort. Cal year, calendar year; dx, diagnosis; IBD, Inflammatory Bowel Disease; OC, oral contraceptive; HRT/ERT, hormone replacement therapy/estrogen replacement therapy; NSAID, non-steroidal anti-inflammatory drug.</description>
        <time_frame>January 1, 1996 – December 31, 2006</time_frame>
        <population>Participants diagnosed with lung cancer who were new antidepressant users.</population>
        <group_list>
          <group group_id="O1">
            <title>Bupropion, Regular Use</title>
            <description>Regular Bupropion use was defined as 4 times per week for 3 months at least 12 months before index date</description>
          </group>
          <group group_id="O2">
            <title>All Non-bupropion Antidepressants, Regular Use</title>
            <description>Regular antidepressant use of non-bupropion was defined as use of non-bupropion antidepressant for 4 times per week for 3 months at least 12 months before index date</description>
          </group>
          <group group_id="O3">
            <title>Tricyclic Antidepressants (TCA), Regular Use</title>
            <description>Regular TCA use was defined as use of tricyclic antidepressant for 4 times per week for 3 months at least 12 months before index date</description>
          </group>
          <group group_id="O4">
            <title>Selective Serotonin Reuptake Inhibitors (SSRI), Regular Use</title>
            <description>Regular SSRI use was defined as use of SSRI antidepressant for 4 times per week for 3 months at least 12 months before index date</description>
          </group>
          <group group_id="O5">
            <title>Other Antidepressants, Regular Use</title>
            <description>Regular ‘other’ antidepressant use was defined as use other antidepressant aside from Bupropion, TCA and SSRI for 4 times per week for 3 months at least 12 months before index date</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Diagnosed With Lung Cancer Who Were Regularly Exposed to the Indicated Antidepressant</title>
          <description>In this outcome, lung cancer is under investigation: Cancer case were nested within a cohort of new antidepressant users. New antidepressant users were defined as no previous antidepressant prescription in the previous 6 months. Lung cancer cases were identified and matched with controls from the same new-user cohort. Cal year, calendar year; dx, diagnosis; IBD, Inflammatory Bowel Disease; OC, oral contraceptive; HRT/ERT, hormone replacement therapy/estrogen replacement therapy; NSAID, non-steroidal anti-inflammatory drug.</description>
          <population>Participants diagnosed with lung cancer who were new antidepressant users.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="240"/>
                <count group_id="O2" value="1172"/>
                <count group_id="O3" value="498"/>
                <count group_id="O4" value="670"/>
                <count group_id="O5" value="233"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cases</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115"/>
                    <measurement group_id="O2" value="250"/>
                    <measurement group_id="O3" value="109"/>
                    <measurement group_id="O4" value="138"/>
                    <measurement group_id="O5" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Controls</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125"/>
                    <measurement group_id="O2" value="922"/>
                    <measurement group_id="O3" value="389"/>
                    <measurement group_id="O4" value="532"/>
                    <measurement group_id="O5" value="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Crude Odds Ratio</param_type>
            <param_value>4.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.2</ci_lower_limit>
            <ci_upper_limit>6.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>3.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.0</ci_lower_limit>
            <ci_upper_limit>4.4</ci_upper_limit>
            <estimate_desc>Adjusted for age, sex, cal year, study site, tumor characteristics, multiple antidepressants exposure, smoking, hysterectomy status, previous depression dx, previous IBD diagnosis, OC use, HRT/ERT use, and NSAID use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Crude Odds Ratio</param_type>
            <param_value>4.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.8</ci_lower_limit>
            <ci_upper_limit>5.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>2.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.9</ci_lower_limit>
            <ci_upper_limit>4.5</ci_upper_limit>
            <estimate_desc>Adjusted for age, sex, cal year, study site, tumor characteristics, multiple antidepressants exposure, smoking, hysterectomy status, previous depression dx, previous IBD diagnosis, OC use, HRT/ERT use, and NSAID use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Crude Odds Ratio</param_type>
            <param_value>4.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.1</ci_lower_limit>
            <ci_upper_limit>6.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>3.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.9</ci_lower_limit>
            <ci_upper_limit>4.5</ci_upper_limit>
            <estimate_desc>Adjusted for age, sex, cal year, study site, tumor characteristics, multiple antidepressants exposure, smoking, hysterectomy status, previous depression dx, previous IBD diagnosis, OC use, HRT/ERT use, and NSAID use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Crude Odds Ratio</param_type>
            <param_value>4.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.8</ci_lower_limit>
            <ci_upper_limit>7.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>3.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.1</ci_lower_limit>
            <ci_upper_limit>5.9</ci_upper_limit>
            <estimate_desc>Adjusted for age, sex, cal year, study site, tumor characteristics, multiple antidepressants exposure, smoking, hysterectomy status, previous depression dx, previous IBD diagnosis, OC use, HRT/ERT use, and NSAID use.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Diagnosed With Bladder Cancer Who Were Regularly Exposed to the Indicated Antidepressant</title>
        <description>In this outcome, bladder cancer is under investigation: Cancer case were nested within a cohort of new antidepressant users. New antidepressant users were defined as no previous antidepressant prescription in the previous 6 months. Bladder cancer cases were identified and matched with controls from the same new-user cohort. Cal year, calendar year; dx, diagnosis; IBD, Inflammatory Bowel Disease; OC, oral contraceptive; HRT/ERT, hormone replacement therapy/estrogen replacement therapy; NSAID, non-steroidal anti-inflammatory drug.</description>
        <time_frame>January 1, 1996 – December 31, 2006</time_frame>
        <population>Participants diagnosed with bladder cancer who were new antidepressant users.</population>
        <group_list>
          <group group_id="O1">
            <title>Bupropion, Regular Use</title>
            <description>Regular Bupropion use was defined as 4 times per week for 3 months at least 12 months before index date</description>
          </group>
          <group group_id="O2">
            <title>All Non-bupropion Antidepressants, Regular Use</title>
            <description>Regular antidepressant use of non-bupropion was defined as use of non-bupropion antidepressant for 4 times per week for 3 months at least 12 months before index date</description>
          </group>
          <group group_id="O3">
            <title>Tricyclic Antidepressants (TCA), Regular Use</title>
            <description>Regular TCA use was defined as use of tricyclic antidepressant for 4 times per week for 3 months at least 12 months before index date</description>
          </group>
          <group group_id="O4">
            <title>Selective Serotonin Reuptake Inhibitors (SSRI), Regular Use</title>
            <description>Regular SSRI use was defined as use of SSRI antidepressant for 4 times per week for 3 months at least 12 months before index date</description>
          </group>
          <group group_id="O5">
            <title>Other Antidepressants, Regular Use</title>
            <description>Regular ‘other’ antidepressant use was defined as use other antidepressant aside from Bupropion, TCA and SSRI for 4 times per week for 3 months at least 12 months before index date</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Diagnosed With Bladder Cancer Who Were Regularly Exposed to the Indicated Antidepressant</title>
          <description>In this outcome, bladder cancer is under investigation: Cancer case were nested within a cohort of new antidepressant users. New antidepressant users were defined as no previous antidepressant prescription in the previous 6 months. Bladder cancer cases were identified and matched with controls from the same new-user cohort. Cal year, calendar year; dx, diagnosis; IBD, Inflammatory Bowel Disease; OC, oral contraceptive; HRT/ERT, hormone replacement therapy/estrogen replacement therapy; NSAID, non-steroidal anti-inflammatory drug.</description>
          <population>Participants diagnosed with bladder cancer who were new antidepressant users.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="853"/>
                <count group_id="O3" value="385"/>
                <count group_id="O4" value="454"/>
                <count group_id="O5" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cases</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="191"/>
                    <measurement group_id="O3" value="88"/>
                    <measurement group_id="O4" value="103"/>
                    <measurement group_id="O5" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Controls</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="662"/>
                    <measurement group_id="O3" value="297"/>
                    <measurement group_id="O4" value="351"/>
                    <measurement group_id="O5" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Crude Odds Ratio</param_type>
            <param_value>2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.7</ci_lower_limit>
            <ci_upper_limit>4.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>2.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.3</ci_lower_limit>
            <ci_upper_limit>3.4</ci_upper_limit>
            <estimate_desc>Adjusted for age, sex, cal year, study site, tumor characteristics, multiple antidepressants exposure, smoking, hysterectomy status, previous depression dx, previous IBD diagnosis, OC use, HRT/ERT use, and NSAID use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Crude Odds Ratio</param_type>
            <param_value>2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.4</ci_lower_limit>
            <ci_upper_limit>3.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.1</ci_lower_limit>
            <ci_upper_limit>3.0</ci_upper_limit>
            <estimate_desc>Adjusted for age, sex, cal year, study site, tumor characteristics, multiple antidepressants exposure, smoking, hysterectomy status, previous depression dx, previous IBD diagnosis, OC use, HRT/ERT use, and NSAID use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Crude Odds Ratio</param_type>
            <param_value>2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.5</ci_lower_limit>
            <ci_upper_limit>3.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.1</ci_lower_limit>
            <ci_upper_limit>3.0</ci_upper_limit>
            <estimate_desc>Adjusted for age, sex, cal year, study site, tumor characteristics, multiple antidepressants exposure, smoking, hysterectomy status, previous depression dx, previous IBD diagnosis, OC use, HRT/ERT use, and NSAID use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Crude Odds Ratio</param_type>
            <param_value>2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.5</ci_lower_limit>
            <ci_upper_limit>4.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>2.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.3</ci_lower_limit>
            <ci_upper_limit>3.9</ci_upper_limit>
            <estimate_desc>Adjusted for age, sex, cal year, study site, tumor characteristics, multiple antidepressants exposure, smoking, hysterectomy status, previous depression dx, previous IBD diagnosis, OC use, HRT/ERT use, and NSAID use.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Diagnosed With Uterine Cancer Who Were Regularly Exposed to the Indicated Antidepressant</title>
        <description>In this outcome, uterine cancer is under investigation: Cancer case were nested within a cohort of new antidepressant users. New antidepressant users were defined as no previous antidepressant prescription in the previous 6 months. Uterine cancer cases were identified and matched with controls from the same new-user cohort. Cal year, calendar year; dx, diagnosis; IBD, Inflammatory Bowel Disease; OC, oral contraceptive; HRT/ERT, hormone replacement therapy/estrogen replacement therapy; NSAID, non-steroidal anti-inflammatory drug.</description>
        <time_frame>January 1, 1996 – December 31, 2006</time_frame>
        <population>Participants diagnosed with uterine cancer who were new antidepressant users.</population>
        <group_list>
          <group group_id="O1">
            <title>Bupropion, Regular Use</title>
            <description>Regular Bupropion use was defined as 4 times per week for 3 months at least 12 months before index date</description>
          </group>
          <group group_id="O2">
            <title>All Non-bupropion Antidepressants, Regular Use</title>
            <description>Regular antidepressant use of non-bupropion was defined as use of non-bupropion antidepressant for 4 times per week for 3 months at least 12 months before index date</description>
          </group>
          <group group_id="O3">
            <title>Tricyclic Antidepressants (TCA), Regular Use</title>
            <description>Regular TCA use was defined as use of tricyclic antidepressant for 4 times per week for 3 months at least 12 months before index date</description>
          </group>
          <group group_id="O4">
            <title>Selective Serotonin Reuptake Inhibitors (SSRI), Regular Use</title>
            <description>Regular SSRI use was defined as use of SSRI antidepressant for 4 times per week for 3 months at least 12 months before index date</description>
          </group>
          <group group_id="O5">
            <title>Other Antidepressants, Regular Use</title>
            <description>Regular ‘other’ antidepressant use was defined as use other antidepressant aside from Bupropion, TCA and SSRI for 4 times per week for 3 months at least 12 months before index date</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Diagnosed With Uterine Cancer Who Were Regularly Exposed to the Indicated Antidepressant</title>
          <description>In this outcome, uterine cancer is under investigation: Cancer case were nested within a cohort of new antidepressant users. New antidepressant users were defined as no previous antidepressant prescription in the previous 6 months. Uterine cancer cases were identified and matched with controls from the same new-user cohort. Cal year, calendar year; dx, diagnosis; IBD, Inflammatory Bowel Disease; OC, oral contraceptive; HRT/ERT, hormone replacement therapy/estrogen replacement therapy; NSAID, non-steroidal anti-inflammatory drug.</description>
          <population>Participants diagnosed with uterine cancer who were new antidepressant users.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="866"/>
                <count group_id="O3" value="371"/>
                <count group_id="O4" value="484"/>
                <count group_id="O5" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cases</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="233"/>
                    <measurement group_id="O3" value="114"/>
                    <measurement group_id="O4" value="124"/>
                    <measurement group_id="O5" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Controls</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="633"/>
                    <measurement group_id="O3" value="257"/>
                    <measurement group_id="O4" value="360"/>
                    <measurement group_id="O5" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Crude Odds Ratio</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.5</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.4</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
            <estimate_desc>Adjusted for age, sex, cal year, study site, tumor characteristics, multiple antidepressants exposure, smoking, hysterectomy status, previous depression dx, previous IBD diagnosis, OC use, HRT/ERT use, and NSAID use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Crude Odds Ratio</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.4</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.3</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
            <estimate_desc>Adjusted for age, sex, cal year, study site, tumor characteristics, multiple antidepressants exposure, smoking, hysterectomy status, previous depression dx, previous IBD diagnosis, OC use, HRT/ERT use, and NSAID use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Crude Odds Ratio</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.5</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.4</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
            <estimate_desc>Adjusted for age, sex, cal year, study site, tumor characteristics, multiple antidepressants exposure, smoking, hysterectomy status, previous depression dx, previous IBD diagnosis, OC use, HRT/ERT use, and NSAID use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Crude Odds Ratio</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.6</ci_lower_limit>
            <ci_upper_limit>2.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.6</ci_lower_limit>
            <ci_upper_limit>1.9</ci_upper_limit>
            <estimate_desc>Adjusted for age, sex, cal year, study site, tumor characteristics, multiple antidepressants exposure, smoking, hysterectomy status†, previous depression dx, previous IBD‡ diagnosis, OC§ use, HRT/ERT use, and NSAID use.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Diagnosed With Breast Cancer Who Were Regularly Exposed to the Indicated Antidepressant</title>
        <description>In this outcome, breast cancer is under investigation: Cancer case were nested within a cohort of new antidepressant users. New antidepressant users were defined as no previous antidepressant prescription in the previous 6 months. Breast cancer cases were identified and matched with controls from the same new-user cohort. Cal year, calendar year; dx, diagnosis; IBD, Inflammatory Bowel Disease; OC, oral contraceptive; HRT/ERT, hormone replacement therapy/estrogen replacement therapy; NSAID, non-steroidal anti-inflammatory drug.</description>
        <time_frame>January 1, 1996 – December 31, 2006</time_frame>
        <population>Participants diagnosed with breast cancer who were new antidepressant users.</population>
        <group_list>
          <group group_id="O1">
            <title>Bupropion, Regular Use</title>
            <description>Regular Bupropion use was defined as 4 times per week for 3 months at least 12 months before index date</description>
          </group>
          <group group_id="O2">
            <title>All Non-bupropion Antidepressants, Regular Use</title>
            <description>Regular antidepressant use of non-bupropion was defined as use of non-bupropion antidepressant for 4 times per week for 3 months at least 12 months before index date</description>
          </group>
          <group group_id="O3">
            <title>Tricyclic Antidepressants (TCA), Regular Use</title>
            <description>Regular TCA use was defined as use of tricyclic antidepressant for 4 times per week for 3 months at least 12 months before index date</description>
          </group>
          <group group_id="O4">
            <title>Selective Serotonin Reuptake Inhibitors (SSRI), Regular Use</title>
            <description>Regular SSRI use was defined as use of SSRI antidepressant for 4 times per week for 3 months at least 12 months before index date</description>
          </group>
          <group group_id="O5">
            <title>Other Antidepressants, Regular Use</title>
            <description>Regular ‘other’ antidepressant use was defined as use other antidepressant aside from Bupropion, TCA and SSRI for 4 times per week for 3 months at least 12 months before index date</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Diagnosed With Breast Cancer Who Were Regularly Exposed to the Indicated Antidepressant</title>
          <description>In this outcome, breast cancer is under investigation: Cancer case were nested within a cohort of new antidepressant users. New antidepressant users were defined as no previous antidepressant prescription in the previous 6 months. Breast cancer cases were identified and matched with controls from the same new-user cohort. Cal year, calendar year; dx, diagnosis; IBD, Inflammatory Bowel Disease; OC, oral contraceptive; HRT/ERT, hormone replacement therapy/estrogen replacement therapy; NSAID, non-steroidal anti-inflammatory drug.</description>
          <population>Participants diagnosed with breast cancer who were new antidepressant users.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3268"/>
                <count group_id="O2" value="23361"/>
                <count group_id="O3" value="10279"/>
                <count group_id="O4" value="13454"/>
                <count group_id="O5" value="5638"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cases</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="302"/>
                    <measurement group_id="O2" value="2173"/>
                    <measurement group_id="O3" value="941"/>
                    <measurement group_id="O4" value="1265"/>
                    <measurement group_id="O5" value="497"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Controls</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2966"/>
                    <measurement group_id="O2" value="21188"/>
                    <measurement group_id="O3" value="9338"/>
                    <measurement group_id="O4" value="12189"/>
                    <measurement group_id="O5" value="5141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Crude Odds Ratio</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.8</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.8</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
            <estimate_desc>Adjusted for age, sex, cal year, study site, tumor characteristics, multiple antidepressants exposure, smoking, hysterectomy status, previous depression dx, previous IBD diagnosis, OC use, HRT/ERT use, and NSAID use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Crude Odds Ratio</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.8</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
            <estimate_desc>Adjusted for age, sex, cal year, study site, tumor characteristics, multiple antidepressants exposure, smoking, hysterectomy status, previous depression dx, previous IBD diagnosis, OC use, HRT/ERT use, and NSAID use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Crude Odds Ratio</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.8</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.8</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
            <estimate_desc>Adjusted for age, sex, cal year, study site, tumor characteristics, multiple antidepressants exposure, smoking, hysterectomy status, previous depression dx, previous IBD diagnosis, OC use, HRT/ERT use, and NSAID use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Crude Odds Ratio</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
            <estimate_desc>Adjusted for age, sex, cal year, study site, tumor characteristics, multiple antidepressants exposure, smoking, hysterectomy status, previous depression dx, previous IBD diagnosis, OC use, HRT/ERT use, and NSAID use.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Diagnosed With Prostate Cancer Who Were Regularly Exposed to the Indicated Antidepressant</title>
        <description>In this outcome, prostate cancer is under investigation: Cancer case were nested within a cohort of new antidepressant users. New antidepressant users were defined as no previous antidepressant prescription in the previous 6 months. Prostate cancer cases were identified and matched with controls from the same new-user cohort. Cal year, calendar year; dx, diagnosis; IBD, Inflammatory Bowel Disease; OC, oral contraceptive; HRT/ERT, hormone replacement therapy/estrogen replacement therapy; NSAID, non-steroidal anti-inflammatory drug.</description>
        <time_frame>January 1, 1996 – December 31, 2006</time_frame>
        <population>Participants diagnosed with prostate cancer who were new antidepressant users.</population>
        <group_list>
          <group group_id="O1">
            <title>Bupropion, Regular Use</title>
            <description>Regular Bupropion use was defined as 4 times per week for 3 months at least 12 months before index date</description>
          </group>
          <group group_id="O2">
            <title>All Non-bupropion Antidepressants, Regular Use</title>
            <description>Regular antidepressant use of non-bupropion was defined as use of non-bupropion antidepressant for 4 times per week for 3 months at least 12 months before index date</description>
          </group>
          <group group_id="O3">
            <title>Tricyclic Antidepressants (TCA), Regular Use</title>
            <description>Regular TCA use was defined as use of tricyclic antidepressant for 4 times per week for 3 months at least 12 months before index date</description>
          </group>
          <group group_id="O4">
            <title>Selective Serotonin Reuptake Inhibitors (SSRI), Regular Use</title>
            <description>Regular SSRI use was defined as use of SSRI antidepressant for 4 times per week for 3 months at least 12 months before index date</description>
          </group>
          <group group_id="O5">
            <title>Other Antidepressants, Regular Use</title>
            <description>Regular ‘other’ antidepressant use was defined as use other antidepressant aside from Bupropion, TCA and SSRI for 4 times per week for 3 months at least 12 months before index date</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Diagnosed With Prostate Cancer Who Were Regularly Exposed to the Indicated Antidepressant</title>
          <description>In this outcome, prostate cancer is under investigation: Cancer case were nested within a cohort of new antidepressant users. New antidepressant users were defined as no previous antidepressant prescription in the previous 6 months. Prostate cancer cases were identified and matched with controls from the same new-user cohort. Cal year, calendar year; dx, diagnosis; IBD, Inflammatory Bowel Disease; OC, oral contraceptive; HRT/ERT, hormone replacement therapy/estrogen replacement therapy; NSAID, non-steroidal anti-inflammatory drug.</description>
          <population>Participants diagnosed with prostate cancer who were new antidepressant users.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3550"/>
                <count group_id="O2" value="17042"/>
                <count group_id="O3" value="7436"/>
                <count group_id="O4" value="9112"/>
                <count group_id="O5" value="4089"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cases</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="326"/>
                    <measurement group_id="O2" value="1480"/>
                    <measurement group_id="O3" value="600"/>
                    <measurement group_id="O4" value="806"/>
                    <measurement group_id="O5" value="363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Controls</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3224"/>
                    <measurement group_id="O2" value="15562"/>
                    <measurement group_id="O3" value="6836"/>
                    <measurement group_id="O4" value="8306"/>
                    <measurement group_id="O5" value="3726"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Crude Odds Ratio</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.0</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.0</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
            <estimate_desc>Adjusted for age, sex, cal year, study site, tumor characteristics, multiple antidepressants exposure, smoking, hysterectomy status, previous depression dx, previous IBD diagnosis, OC use, HRT/ERT use, and NSAID use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Crude Odds Ratio</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.0</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.0</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
            <estimate_desc>Adjusted for age, sex, cal year, study site, tumor characteristics, multiple antidepressants exposure, smoking, hysterectomy status, previous depression dx, previous IBD diagnosis, OC use, HRT/ERT use, and NSAID use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Crude Odds Ratio</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
            <estimate_desc>Adjusted for age, sex, cal year, study site, tumor characteristics, multiple antidepressants exposure, smoking, hysterectomy status, previous depression dx, previous IBD diagnosis, OC use, HRT/ERT use, and NSAID use.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Crude Odds Ratio</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.8</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
            <estimate_desc>Adjusted for age, sex, cal year, study site, tumor characteristics, multiple antidepressants exposure, smoking, hysterectomy status, previous depression dx, previous IBD diagnosis, OC use, HRT/ERT use, and NSAID use.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>This is a retrospective study of pre-existing data; thus, no assessments for Serious or Non-serious Adverse Events were performed.</desc>
      <group_list>
        <group group_id="E1">
          <title>New Antidepressant Exposure in Colorectal Cancer: Cases</title>
          <description>New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Colorectal Cancer: Cases</description>
        </group>
        <group group_id="E2">
          <title>New Antidepressant Exposure in Colorectal Cancer: Controls</title>
          <description>New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Colorectal Cancer: Controls</description>
        </group>
        <group group_id="E3">
          <title>New Antidepressant Exposure in Lung Cancer: Cases</title>
          <description>New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Lung Cancer: Cases</description>
        </group>
        <group group_id="E4">
          <title>New Antidepressant Exposure in Lung Cancer: Controls</title>
          <description>New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Lung Cancer: Controls</description>
        </group>
        <group group_id="E5">
          <title>New Antidepressant Exposure in Bladder Cancer: Cases</title>
          <description>New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Bladder Cancer: Cases</description>
        </group>
        <group group_id="E6">
          <title>New Antidepressant Exposure in Bladder Cancer: Controls</title>
          <description>New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Bladder Cancer: Controls</description>
        </group>
        <group group_id="E7">
          <title>New Antidepressant Exposure in Uterine Cancer: Cases</title>
          <description>New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Uterine Cancer: Cases</description>
        </group>
        <group group_id="E8">
          <title>New Antidepressant Exposure in Uterine Cancer: Controls</title>
          <description>New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Uterine Cancer: Controls</description>
        </group>
        <group group_id="E9">
          <title>New Antidepressant Exposure in Breast Cancer: Cases</title>
          <description>New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Breast Cancer: Cases</description>
        </group>
        <group group_id="E10">
          <title>New Antidepressant Exposure in Breast Cancer: Controls</title>
          <description>New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Breast Cancer: Controls</description>
        </group>
        <group group_id="E11">
          <title>New Antidepressant Exposure in Prostate Cancer: Cases</title>
          <description>New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Prostate Cancer: Cases</description>
        </group>
        <group group_id="E12">
          <title>New Antidepressant Exposure in Prostate Cancer: Controls</title>
          <description>New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Prostate Cancer: Controls</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

